1 / 23

Resection and Transplantation for HCC in Patients with NAFLD

Resection and Transplantation for HCC in Patients with NAFLD. Julie Heimbach Professor of Surgery Chair, division of transplantation Surgery Mayo Clinic. Outline : Resection Differences in patient characteristics for NAFLD/HCC and non-NAFLD/HCC Outcomes Transplant

lamonts
Download Presentation

Resection and Transplantation for HCC in Patients with NAFLD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Resection and Transplantation for HCC in Patients with NAFLD Julie Heimbach Professor of Surgery Chair, division of transplantation Surgery Mayo Clinic

  2. Outline: • Resection • Differences in patient characteristics for NAFLD/HCC and non-NAFLD/HCC • Outcomes • Transplant • Incidence and demographics • Outcomes *NAFLD/metabolic syndrome may also be present in setting of ALD, overlap with other etiologies Berot and Adams Expert Reviews GI and Hep 2019

  3. Meta-analysis of case control and cohort studies assessing risk of HCC in patients with DM Diabetes Increases Risk of HCC in Patients With or Without NASH El Serag. Clin Gastro Hep. 2006. 1 Effect p 10 Lower df 0.1 Upper 2.5 2.5 2.5 2.0 2.8 2.1 2.5 1.5 1.8 1.5 1.9 1.3 2.2 1.0 2.1 1.0 2.9 3.1 3.2 3.1 3.7 4.1 3.0 2.4 23 12 11 8 8 6 6 10 <0.01 <0.01 <0.01 <0.01 <0.01 0.02 <0.01 0.26 All Studies (n = 25) Case-Control (n = 13) Cohort (n = 12) US studies (n = 9) European studies (n = 9) Japanese studies (n = 7) Population controls (n = 7) Hospital controls (n = 11) Most studies adjusted for multiple comorbidities, but not always for BMI

  4. Obesity Increases Risk of Primary Liver Cancer in Patients With or Without NASH Chen. Eur J Cancer. 2012. Studies Obesity (BMI >30) RR (95%CI) Moller et al. (1994) Wolk et al. (2001) Nair et al. (2002) Calle et al. (2003) Samanic et al. (2004) Oh et al. (2005) Rapp et al. (2005) Batty et al. (2005) Kuriyama et al. (2005) Samanic et al. (2006) N’Kontchou et al. (2006) Ioannou et al. (2007) Jee et al. (2008) Chen et al. (2008) Ohki et al. (2008) Joshi et al. (2008) Wang et al. (2009) Loomba et al. (2010) Hart et al. (2010) Overall (I-squared = 67.9%, p -0.000) 1.90 (1.50, 2.50) 2.40 (1.60, 3.40) 1.65 (1.22, 2.22) 2.03 (1.69, 2.43) 1.33 (1.19, 1.48) 1.53 (1.06, 2.22) 1.67 (0.75, 3.72) 3.02 (0.80, 11.40) 1.04 (0.51, 2.11) 3.13 (2.04, 4.79) 2.80 (2.00, 4.00) 2.50 (1.30, 4.90) 1.54 (1.26, 1.88) 2.06 (1.22, 3.46) 3.10 (1.41, 6.81) 1.08 (0.67, 1.72) 1.70 (1.02, 2.08) 1.43 (1.03, 1.98) 2.84 (1.34, 6.02) 1.83 (1.59, 2.11) .2 .5 1 2 5

  5. Single-center analysis 1995-2014- French • N=323 patients undergoingresection for HCC • Prevelence of NAFLD increased over studyperiod (2% to 20%) Pais et al, APT 2017

  6. HCC+ NAFLD more likely to be in absence of fibrosis/cirrhosis, and at older age (71 v 51) Prevalence of metabolic risk factors increased in the study period for all pts Pais et al, APT 2017

  7. Etiology of cirrhosis not related to outcome Pais et al, APT 2017

  8. Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma Koh et al JACS 2019 • Two centers, N=844 non-NAFLD HCC versus N=152 NAFLD HCC, Singapore. 2000-2015 • NAFLD pts were older, more often female, and had greater blood loss, LOS, and complications • Superior 5 year outcomes for NAFLD patients (HR=0.67,p=0.04) • Comorbidities (age, CHF, tumor characteristics, Childs B) contributed to worse survival

  9. Yang et al J GastrointSurg 2019 • Multi-center 2003-2011, China • N=1483, undergoing resection for HCC • 96 (6.5%) NAFLD, 1387 (n=93.5%) HBV • NAFLD older, more often female, less likely to have cirrhosis (30% vs 70%), similar survival, similar morbidity before, after PSM

  10. Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC • Multi-center, Italy 2000-2012, N=1563, with 96 NAFLD HCC matched to HCV patients • Similar peri-operative outcomes– • risk factors: cirrhosis, major hepatectomy, MELD>8 but not NASH • NAFLD had better long term outcome (pre-DAA era) Vigano et al J Hep 2016

  11. Outcomes of Curative Treatment for HepatocellularCancer in Nonalcoholic Steatohepatitis VersusHepatitis C and Alcoholic Liver Disease • N=321, 2000-2010, 52 NAFLD and 168 HCV, ALD single US center • Older (68 vs 59), more often female, less likely to have cirrhosis, • No difference in recurrence free survival but overall survival better in NAFLD Reddy et al Hepatology 2012

  12. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non alcoholic fatty liver disease Wong et al. AP&T 2017 transplant resection NAFLD NAFLD • SEER data, 1991-2011. N=17,664 • NAFLD 46% less likely to be offered curative therapy, but not an predictor of worse survival

  13. NAFLD more likely to be resected w/o cirrhosis and transplanted with cirrhosis Gawrieh et al AP&T 2019 • 5 US centers, 2000-2014 • N=5144 pts with HCC. 26% had NAFLD • Resection (HR=0.24) and transplantation (HR=0.16) associated with improved survival

  14. Outcomes of LT for NASH: an ELTR study Haldar et al J Hep 2019 NASH

  15. ELTR study continued • 1.4% TX for NASH in 2002 up to 8.6% in 2016. 39.1% of NASH patients had HCC, vs 28.9 % of non-NASH • NASH was not an independent predictor of survival in patients with or without HCC • Causes of death post LT were similar in NASH and non-NASH patients (infection, CV); there was more extra-hepatic malignancy in ALD and recurrent disease in HCV

  16. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates • SRTR 2002-2016 • N=158,000: HCC rose from 6.4% in 2002 to 23% in 2016 • HCV is still most common cause for HCC, NASH rising faster and is currently second. • HCC recurrence is lowest in NASH, highest in HBV Younossi et al CGH 2019

  17. 2004-2014, UCSF and University of Toronto, N=929 transplanted for HCC, 60 for NASH • NASH patients were older, and had more females (38% vs 18%) • Tumors characteristics were similar (size, number, microvascular invasion) • Outcomes similar Sadler et al Transplantation 2018

  18. Comparison for beyond Milan only, favored NASH patients (n=19) • Higher proportion of NASH had microvascular invasion, yet still had more favorable outcome • ? Unknown whether NASH related tumors inherently less aggressive Sadler et al Transplantation 2018

  19. Impact of obesity on outcome of LT for HCC? Siegel et al Transplantation 2012 • Single center, US N=342 LT for HCC. 1999-2010 • BMI>30 associated with increased risk of death, microvascular invasion, and HCC recurrence

  20. Impact of obesity on outcome of LT for HCC? Ata et al HPB 2019 • UNOS data N=8352 LT for HCC • 2002-2013 • Donor and recipient BMI

  21. Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC Shingina et al Transplantation 2019 • Rates of obesity in US are 39.8% of adults and 18.5 % of children • Analysis of birth cohorts to determine future trends in LT registration due to NASH, with and without HCC

  22. Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC Shingina et al Transplantation 2019 Observed LT registration by age group in NASH patients Observed and projected LT registration for NASH+HCC

  23. Summary • HCC-NAFLD resection patients tend to be older, more often female, more metabolic disease, less cirrhosis, with similar tumor characteristics and similar outcomes • HCC-NAFLD transplant patients also older, more female, similar outcomes. Obesity not likely to impact outcome for selected patients. Rising indication for LT

More Related